Converging on an HIV Vaccine

See allHide authors and affiliations

Science  16 Sep 2011:
Vol. 333, Issue 6049, pp. 1589-1590
DOI: 10.1126/science.1211919

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Three decades after the discovery of AIDS we still do not have a vaccine against the causative agent, the human immunodeficiency virus (HIV). Multidrug therapy can extend life and health for those with HIV, but only holds the virus at bay, making treatment a lifetime proposition. Access to treatment or other promising infection prevention measures such as topical microbicides (1) are an economic and social challenge (2). A vaccine would be a simple and direct strategy for prevention. On pages 1593 and 1633 of this issue, Wu et al. (3) and Scheid et al. (4) detail the trajectory of an immune response to natural HIV infection that may provide a path to a vaccine.